SLC5A2 and gout: To our knowledge, one US study25 has noted that the gout incidence risk rate was reduced by more than 30% in patients receiving SGLT2 inhibitors compared with prescribed GLP-1 agonists; this risk reduction rate was larger than the rate shown with our data.